SCHEMBL3405607

SCHEMBL3405607

Cc1ccn(-c2cc(Cl)c3cccnc3n2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.46
MAPT P10636 3/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
ATM Q13315 1/20 0.46
ADORA2A P29274 4/20 0.42
IDO1 P14902 4/20 0.38
CCR1 P32246 1/20 0.38
CCR8 P51685 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
JAK2 O60674 1/20 0.36
TYK2 P29597 1/20 0.36
AVPR2 P30518 1/20 0.36
KDM4E B2RXH2 2/20 0.36
GAA P10253 1/20 0.36
TNKS O95271 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10193135 0.83 MAPT (0.45) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL12424756 0.77 TGFBR1 (0.41) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL13968416 0.76 MAPT (0.49) L3MBTL1MAPTSMN1; SMN2NPC1IDO1
SCHEMBL2328238 0.74 NPC1 (0.37) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL3382263 0.72 IKBKE (0.50) IDO1IGF1R
SCHEMBL21143725 0.71 MAPT (0.51) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL2297621 0.69 KDM4E (0.43) L3MBTL1MAPTSMN1; SMN2ADORA2AIDO1
SCHEMBL247512 0.69 L3MBTL1 (0.52) L3MBTL1MAPTSMN1; SMN2IDO1CCR1
SCHEMBL1907360 0.68 MAPT (0.63) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL38651177 0.68 MAPT (0.63) L3MBTL1MAPTRAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585461-B1 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GMBH (DE) 2020-02-26 EP disclosed
US-8791113-B2 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer MERCK PATENT GMBH (DE) 2014-07-29 US disclosed
US-8791113-B2 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer MERCK PATENT GMBH (DE) 2014-07-29 US disclosed
US-20130102603-A1 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-04-25 US disclosed
US-20130102603-A1 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-04-25 US disclosed
WO-2012000595-A1 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GMBH (DE) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102603-A1 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER TGFBR1, TAB1, TGFBR2 L3MBTL1 3707/4885MAPT 4149/4885RAB9A 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.